AVI BioPharma, Inc. (NASDAQ:AVII)

CAPS Rating: 4 out of 5

A biopharmaceutical company developing therapeutic products principally based on third-generation NEUGENE antisense technology.

Recs

1
Player Avatar closetdoor (64.60) Submitted: 9/27/2006 5:08:41 PM : Outperform Start Price: $3.57 AVII Score: -84.60

This is speculative but I think it will do well in the near future.

Report this Post Reply

Featured Broker Partners


Advertisement